Literature DB >> 6197741

Human autologous mixed lymphocyte reactions (a review).

F Indiveri, A Barabino, I Pierri, V Grifoni.   

Abstract

The literature concerning the autologous mixed lymphocyte reactions has been reviewed. This analysis supports the following conclusions: human subjects have self-responsive cells which are capable of proliferating when co-cultured with irradiated autologous non-T or Ia+ T cells. Since monoclonal antibodies recognizing distinct determinants of Ia antigen have different effects on AMLR with non-T cells and on Ia+ type AMLR, there is the possibility that different Ia molecule determinants have different functional role in the process of cell-to-cell interaction. The presence of AMLR abnormalities in disease strongly suggests that reactivity among different cell subsets plays a role in immunological homeostasis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6197741     DOI: 10.1007/bf02906920

Source DB:  PubMed          Journal:  Ric Clin Lab        ISSN: 0390-5748


  4 in total

1.  Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans.

Authors:  A Morgano; I Pierri; R Stagnaro; M Setti; F Puppo; F Indiveri
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.

Authors:  G Parmiani; G Fossati; D Taramelli; A Anichini; A Balsari; C Gambacorti-Passerini; G Sciorelli; N Cascinelli
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

3.  Activation-induced FoxP3 expression regulates cytokine production in conventional T cells stimulated with autologous dendritic cells.

Authors:  Derek J Cavatorta; Hollis N Erb; M Julia Felippe
Journal:  Clin Vaccine Immunol       Date:  2012-08-01

4.  Vaccines against glioblastoma: reflections on the ICT-107 phase IIb trial.

Authors:  Steven De Vleeschouwer
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.